Skip to main content
. Author manuscript; available in PMC: 2015 Jan 13.
Published in final edited form as: Cancer Cell. 2014 Jan 13;25(1):37–48. doi: 10.1016/j.ccr.2013.12.004

Figure 4. The anti-tumor effect of anti-EGFR-IFNβ requires IFNAR expression on host bone marrow-derived cells.

Figure 4

A) WT and Ifnar1-/- B6 mice (n=5/group) were injected subcutaneously with 5×105 B16-EGFR-SIY cells and treated with 25 μg of anti-EGFR-IFNβ or control Ab on days 14, 18, and 22. The tumor growth was monitored twice a week. B) Seven days after the last treatment, dLN and spleen cells were collected and IFNγ producing in supernatant was detected by CBA assay. C) Thirty days after indicated bone marrow chimera reconstitution, mice were injected subcutaneously with 7×105 B16-EGFR-SIY and treated with 25μg of anti-EGFR-IFNβ or control Ig on days 14, 18, and 22. Tumor growth was measured and compared twice a week. *, p < 0.05, compared to control group. Mean + SEM are shown. One of two representative experiments is shown.